DUBLIN – H. Lundbeck A/S is acquiring Prexton Therapeutics Ltd. for €100 million up front (US$123 million) and up to €805 million more in development, regulatory and commercial milestones, in a deal that gives it ownership of foliglurax (PXT-002331), a first-in-class metabotropic glutamate receptor 4 (mGluR4) agonist currently undergoing a phase II trial as adjunct therapy in Parkinson's disease.